Advertisement
Home 2017

Yearly Archives: 2017

Ogivri (trastuzumab-dkst) has been approved by the U.S. Food and Drug Administration as the nation's first biosimilar drug to treat certain breast and stomach cancers

FDA Approves Biosimilar Ogivri for Breast, Stomach Cancers

0
Ogivri is approved to treat HER2+ breast and gastric or gastroesophageal junction adenocarcinoma cancers
Eating raw almonds

Almonds With/Without Chocolate May Improve Lipid Profiles

0
Findings based on a small study assessing diet combinations in overweight people
Certain clinical factors

Study IDs Clinical Factors Tied to Free Tissue Transfer Reoperation

0
Findings among patients undergoing free tissue transfer for head, neck cancer-related defects
A decision pathway has been developed to guide management of acute bleeding in patients treated with oral anticoagulants; the decision pathway was published online Dec. 1 in the Journal of the American College of Cardiology.

ACC Guides Treatment of Bleeding With Oral Anticoagulation

0
Pathway supports clinician decision making during management of patients with bleeding complications
Targeting can enhance accumulation of nanoparticles to graft endothelial cells of human kidneys undergoing ex vivo normothermic machine perfusion

Targeting Ups Nanoparticle Delivery to Graft Endothelial Cells

0
Anti-CD31 antibody selectively enhances targeting of NPs to graft ECs of human kidney undergoing NMP
Sublocade

FDA Approves Once-Monthly Injection for Opioid Addiction

0
Sublocade has been shown to reduce opioid withdrawal symptoms and the desire to use opioids
Adolescents with depression who are poor responders to treatment do not have more densely connected networks

Network Density Not Linked to Response in Teen Depression

0
No significant association between higher network strength and poorer outcomes
From 1997 to 2014

Differences in Cancer Survival by Type of Insurance

0
Survival up in patients with private insurance, Medicare; no change or drop with other, no insurance
Older ophthalmologists are less likely than younger ones to receive unsolicited patient complaints

Older Ophthalmologists Less Likely to Have Patient Complaints

0
Risk for incurring unsolicited patient complaints higher for those aged 41 to 50, 31 to 40 versus ≥71
For stage I non-small-cell lung cancer

Lobectomy Beats SBRT Survival in Early-Stage NSCLC

0
Higher cancer mortality for SBRT versus lobectomy; no difference for SBRT, sublobar resection